Cellectar Biosciences, Inc.CLRBNASDAQ
Loading
Year-over-year operating cash flow growth rate
Latest
-1.61%
↑ 66% vs avg
Percentile
P64
Within normal range
Streak
2 qtr
Consecutive declineDecelerating
Average
-4.74%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -1.61% |
| Q3 2025 | 16.43% |
| Q2 2025 | 45.48% |
| Q1 2025 | 14.02% |
| Q4 2024 | -19.05% |
| Q3 2024 | 35.18% |
| Q2 2024 | -5.83% |
| Q1 2024 | -39.25% |
| Q4 2023 | -18.94% |
| Q3 2023 | -7.15% |
| Q2 2023 | -4.82% |
| Q1 2023 | 3.08% |
| Q4 2022 | -5.68% |
| Q3 2022 | -21.81% |
| Q2 2022 | -14.24% |
| Q1 2022 | -11.72% |
| Q4 2021 | 29.83% |
| Q3 2021 | 6.50% |
| Q2 2021 | -44.68% |
| Q1 2021 | -22.85% |
| Q4 2020 | -10.47% |
| Q3 2020 | -14.83% |
| Q2 2020 | 13.16% |
| Q1 2020 | -30.99% |
| Q4 2019 | 24.35% |
| Q3 2019 | -33.60% |
| Q2 2019 | 5.77% |
| Q1 2019 | -2.62% |
| Q4 2018 | 7.59% |
| Q3 2018 | -16.63% |
| Q2 2018 | 20.06% |
| Q1 2018 | -12.67% |
| Q4 2017 | -11.12% |
| Q3 2017 | 4.52% |
| Q2 2017 | 10.84% |
| Q1 2017 | -27.19% |
| Q4 2016 | -6.11% |
| Q3 2016 | -16.40% |
| Q2 2016 | -4.59% |
| Q1 2016 | -21.68% |